Home › Companies › LYELL IMMUNOPHARMA INC. › 2024-2025
At LYELL IMMUNOPHARMA INC.'s shareholder meeting held May 15, 2025, in the 2024-2025 proxy season, 100 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 511 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding advisory basis, of the compensation of the company's named executive… — FOR was 99.0% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: LYELL IMMUNOPHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 21, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and LYELL IMMUNOPHARMA INC.’s Form 8-K, filed May 21, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 15, 2025: 4 items on LYELL IMMUNOPHARMA INC.’s Form 8-K, filed May 21, 2025: 4 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore LYELL IMMUNOPHARMA INC. in the interactive database Compare manager voting policies
These tallies are LYELL IMMUNOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 21, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Catherine Friedman | 156,345,397 | -- | -- | 5,956,389 | 50,056,512 | 96% | Not verified | — |
| 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. | 212,014,389 | 288,042 | 55,867 | -- | -- | 99.8% | Not verified | — |
| 3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. | 160,688,745 | 1,547,344 | 65,697 | -- | 50,056,512 | 99.0% | Not verified | — |
| 4. To approve a series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio in the range of 1-for-10 to 1-for-25, with such ratio | 199,897,130 | 12,368,486 | 92,682 | -- | -- | 94% | Not verified | — |
Source: LYELL IMMUNOPHARMA INC., Form 8-K, filed with the SEC on May 21, 2025 — read the filing on EDGAR.
Each item below shows how the 100 asset managers that disclosed a LYELL IMMUNOPHARMA INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Director: Catherine Friedman
LYELL IMMUNOPHARMA INC.’s own tally for this item (“Elect Director: Catherine Friedman”): 156,345,397 for, 5,956,389 withheld, per its Form 8-K filed May 21, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 29,446,930 for, 804,059 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,636,834 | 0 | 0 | 0 | For |
| BlackRock | 6,948,250 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,947,430 | 0 | 0 | 0 | For |
| Fidelity | 3,894,070 | 0 | 0 | 0 | For |
| Charles Schwab | 1,613,970 | 0 | 0 | 0 | For |
| TIAA | 585,273 | 0 | 0 | 0 | For |
| Invesco | 326,291 | 0 | 0 | 0 | For |
| SEI | 323,853 | 0 | 0 | 0 | For |
| Equitable | 101,798 | 0 | 0 | 220,790 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 300,790 | 0 | 0 | 0 | For |
| Global X | 259,023 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 0 | 246,349 | Withhold |
| John Hancock | 123,925 | 0 | 0 | 25,447 | Mixed |
| Lincoln Financial | 125,800 | 0 | 0 | 0 | For |
| Pacific Life | 89,778 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 78,727 | Withhold |
| Bridge Builder Trust | 73,626 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 61,970 | Withhold |
| Voya | 0 | 0 | 0 | 50,329 | Withhold |
| ProShares | 0 | 0 | 0 | 39,827 | Withhold |
| Nationwide | 19,365 | 0 | 0 | 17,379 | Mixed |
| State Street | 30,235 | 0 | 0 | 0 | For |
| DWS | 0 | 0 | 0 | 24,760 | Withhold |
| Calvert | 0 | 0 | 0 | 17,114 | Withhold |
| Victory Capital | 0 | 0 | 0 | 11,179 | Withhold |
Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).
94% Majority: yes · of votes cast
Description as filed by funds: Approval of a series of alternate amendments to the company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio in the range of 1-for-10 to 1-for-25, with such ratio to be determined in the discretion of the company's board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the company's board of directors in its sole discretion.
LYELL IMMUNOPHARMA INC.’s own tally for this item (“4. To approve a series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio in the range of 1-for-10 to 1-for”): 199,897,130 for, 12,368,486 against, per its Form 8-K filed May 21, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 30,250,989 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,636,834 | 0 | 0 | 0 | For |
| BlackRock | 6,948,250 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,947,430 | 0 | 0 | 0 | For |
| Fidelity | 3,894,070 | 0 | 0 | 0 | For |
| Charles Schwab | 1,613,970 | 0 | 0 | 0 | For |
| TIAA | 585,273 | 0 | 0 | 0 | For |
| Invesco | 326,291 | 0 | 0 | 0 | For |
| SEI | 323,853 | 0 | 0 | 0 | For |
| Equitable | 322,588 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 300,790 | 0 | 0 | 0 | For |
| Global X | 259,023 | 0 | 0 | 0 | For |
| ETF Series Solutions | 246,349 | 0 | 0 | 0 | For |
| John Hancock | 149,372 | 0 | 0 | 0 | For |
| Lincoln Financial | 125,800 | 0 | 0 | 0 | For |
| Pacific Life | 89,778 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 78,727 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 73,626 | 0 | 0 | 0 | For |
| Northern Trust | 61,970 | 0 | 0 | 0 | For |
| Voya | 50,329 | 0 | 0 | 0 | For |
| ProShares | 39,827 | 0 | 0 | 0 | For |
| Nationwide | 36,744 | 0 | 0 | 0 | For |
| State Street | 30,235 | 0 | 0 | 0 | For |
| DWS | 24,760 | 0 | 0 | 0 | For |
| Calvert | 17,114 | 0 | 0 | 0 | For |
| Victory Capital | 11,179 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
99.0% Majority: yes · of votes cast
Description as filed by funds: Approval, on a non-binding advisory basis, of the compensation of the company's named executive officers.
LYELL IMMUNOPHARMA INC.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”): 160,688,745 for, 1,547,344 against, per its Form 8-K filed May 21, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,636,834 | 0 | 0 | 0 | For |
| BlackRock | 6,948,250 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,947,430 | 0 | 0 | 0 | For |
| Fidelity | 3,894,070 | 0 | 0 | 0 | For |
| Charles Schwab | 1,613,970 | 0 | 0 | 0 | For |
| TIAA | 0 | 585,273 | 0 | 0 | Against |
| Invesco | 326,291 | 0 | 0 | 0 | For |
| SEI | 323,853 | 0 | 0 | 0 | For |
| Equitable | 322,588 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 300,790 | 0 | 0 | 0 | For |
| Global X | 259,023 | 0 | 0 | 0 | For |
| ETF Series Solutions | 246,349 | 0 | 0 | 0 | For |
| John Hancock | 149,372 | 0 | 0 | 0 | For |
| Lincoln Financial | 125,800 | 0 | 0 | 0 | For |
| Pacific Life | 89,778 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 78,727 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 73,626 | 0 | 0 | 0 | For |
| Northern Trust | 61,970 | 0 | 0 | 0 | For |
| Voya | 50,329 | 0 | 0 | 0 | For |
| ProShares | 39,827 | 0 | 0 | 0 | For |
| Nationwide | 36,744 | 0 | 0 | 0 | For |
| State Street | 30,235 | 0 | 0 | 0 | For |
| DWS | 24,760 | 0 | 0 | 0 | For |
| Calvert | 0 | 17,114 | 0 | 0 | Against |
| Victory Capital | 11,179 | 0 | 0 | 0 | For |
Fund voting reports, all 34 managers: 29,646,768 for, 604,221 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Foresite Capital Management IV, LLC | 16,007,999 | 0 | 0 | 0 | For |
| Foresite Capital Management V, LLC | 8,133,047 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,514,503 | 0 | 0 | 0 | For |
| GV Management Company, L.L.C. | 5,865,125 | 0 | 0 | 0 | For |
| Decheng Capital LLC | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 4,359,804 | 0 | 0 | 0 | For |
| State Street | 3,397,382 | 9,619 | 0 | 0 | For |
| BlackRock | 3,377,761 | 0 | 0 | 0 | For |
| Charles Schwab | 1,613,970 | 0 | 0 | 0 | For |
| BROWN ADVISORY INC | 1,519,807 | 0 | 0 | 0 | For |
| Citadel | 1,331,880 | 0 | 0 | 0 | For |
| TAKEDA PHARMACEUTICAL CO LTD | 823,317 | 0 | 0 | 0 | For |
| Northern Trust | 760,936 | 0 | 0 | 0 | For |
| Nuveen | 0 | 641,173 | 0 | 0 | Against |
| CANADA PENSION PLAN INVESTMENT BOARD | 588,235 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 544,559 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 486,683 | 0 | 0 | 0 | For |
| Clarius Group, LLC | 399,168 | 0 | 0 | 0 | For |
| Invesco | 384,749 | 0 | 0 | 0 | For |
| SEI | 324,822 | 0 | 0 | 0 | For |
| Two Sigma | 262,611 | 0 | 0 | 0 | For |
| AllianceBernstein | 220,790 | 0 | 0 | 0 | For |
| Vanguard | 179,733 | 0 | 0 | 0 | For |
| BBR PARTNERS, LLC | 164,041 | 0 | 0 | 0 | For |
| Renaissance | 117,042 | 0 | 0 | 0 | For |
Institutional-manager reports, all 76 managers: 58,098,665 for, 774,842 against, 382,764 not voted, 5,795,032 unknown. Showing the 25 largest; every one is in the interactive database (link above).
99.8% Majority: yes · of votes cast
Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for its fiscal year ending December 31, 2025.
LYELL IMMUNOPHARMA INC.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 212,014,389 for, 288,042 against, per its Form 8-K filed May 21, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 30,250,989 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,636,834 | 0 | 0 | 0 | For |
| BlackRock | 6,948,250 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,947,430 | 0 | 0 | 0 | For |
| Fidelity | 3,894,070 | 0 | 0 | 0 | For |
| Charles Schwab | 1,613,970 | 0 | 0 | 0 | For |
| TIAA | 585,273 | 0 | 0 | 0 | For |
| Invesco | 326,291 | 0 | 0 | 0 | For |
| SEI | 323,853 | 0 | 0 | 0 | For |
| Equitable | 322,588 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 300,790 | 0 | 0 | 0 | For |
| Global X | 259,023 | 0 | 0 | 0 | For |
| ETF Series Solutions | 246,349 | 0 | 0 | 0 | For |
| John Hancock | 149,372 | 0 | 0 | 0 | For |
| Lincoln Financial | 125,800 | 0 | 0 | 0 | For |
| Pacific Life | 89,778 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 78,727 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 73,626 | 0 | 0 | 0 | For |
| Northern Trust | 61,970 | 0 | 0 | 0 | For |
| Voya | 50,329 | 0 | 0 | 0 | For |
| ProShares | 39,827 | 0 | 0 | 0 | For |
| Nationwide | 36,744 | 0 | 0 | 0 | For |
| State Street | 30,235 | 0 | 0 | 0 | For |
| DWS | 24,760 | 0 | 0 | 0 | For |
| Calvert | 17,114 | 0 | 0 | 0 | For |
| Victory Capital | 11,179 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 254,939,222 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.78% |
| 2 | BlackRock | 2.73% |
| 3 | T. Rowe Price | 1.94% |
| 4 | Fidelity | 1.53% |
| 5 | Charles Schwab | 0.63% |
| 6 | TIAA | 0.23% |
| 7 | Invesco | 0.13% |
| 8 | SEI | 0.13% |
| 9 | Equitable | 0.13% |
| 10 | QUANTITATIVE MASTER SERIES LLC | 0.12% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Foresite Capital Management IV, LLC | 6.28% |
| 2 | Foresite Capital Management V, LLC | 3.19% |
| 3 | T. Rowe Price | 2.56% |
| 4 | GV Management Company, L.L.C. | 2.30% |
| 5 | Decheng Capital LLC | 2.27% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.71% |
| 7 | State Street | 1.34% |
| 8 | BlackRock | 1.32% |
| 9 | Charles Schwab | 0.78% |
| 10 | BROWN ADVISORY INC | 0.60% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Robert Nelsen | 14.41% | DEF14A |
| Entities affiliated with ARCH Venture Partners | 14.28% | DEF14A |
| Glaxo Group Limited | 11.87% | DEF14A |
| Milky Way Investments Group Limited | 7.91% | DEF14A |
| Entities affiliated with Foresite Capital | 7.64% | DEF14A |
| James Tananbaum | 7.64% | 13G |
| Gemini Investments, L.P. | 5.92% | DEF14A |
| BlackRock | 4.99% | 13F |
| Richard D. Klausner, M.D. | 4.77% | DEF14A |
| Vanguard Group | 3.82% | 13F |
Percentages above are of 254,939,222 shares outstanding, as reported by LYELL IMMUNOPHARMA INC. on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LYELL IMMUNOPHARMA INC.’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
LYELL IMMUNOPHARMA INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “LYELL IMMUNOPHARMA (LYEL) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/lyell-immunopharma-inc/2025 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.